"I think it's a really nice synergy between the 2 technologies," says Wayne G. Brisbane, MD.

"The radiologist more than ever has to be part of the care team," says Phillip H. Kuo, MD, PhD, FACR.

“We are pleased that a first patient has been imaged in the CA-NINE trial, which supports potential label expansion for TLX250-CDx into recurrent, metastatic disease,” says David N. Cade.

"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.

The overall report rate per unit sold of the PEG hydrogel spacers was 0.40%.

In total, the phase 3 UTOPIA trial plans to enroll 87 patients with LG-IR-NMIBC to assess the safety and efficacy of UGN-103.

“The toxicity benefits of aggressive margin reduction persist beyond the acute phase post-SBRT," the authors wrote.

Pastuszak discusses the evolving nature of understanding how testosterone therapy post-radiation for prostate cancer may beneficial or harmful to patients, and how to navigate the decision.

Overall, a total of 693 patients received a PEG spacer in 2017 and 2510 received one in 2022, an increase of 262%.

Soumyajit Roy, MS, MBBS, explains how findings showing 5-year biochemical recurrence status may predict prostate cancer cure should alter the clinician-patient interaction.

At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.

The 3-year biochemical progression-free survival was 61%, and the 3-year radiographic progression-free survival was 67%.

Zaorsky discusses the patient safety misconceptions around radiotherapy for RCC, and considering patient-reported outcomes in future randomized controlled trials.

Findings from RAPTOR suggest 5-year biochemical recurrence may be a good indication of prostate cancer cure status.

The estimated 10-year cumulative incidence of PCSM was 1.2% for those who did not experience biochemical recurrence within 5 years of radiotherapy vs 29.0% among those who did.

Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer.

"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS.

Zaorsky discusses his team's ASTRO 2024 abstract showing clear benefit of radiotherapy and ablation in reduced kidney effects in patients with RCC.

“Pembrolizumab maintenance therapy after SABR boost to bladder tumor and concurrent radio-chemotherapy was well tolerated with promising efficacy in the early analysis," said Shang-bin Qin, MD.

“At a median follow-up of 37 months, we saw that failure-free survival was statistically significant, with 2 times more events seen in the control arm," said Colin Belliveau, MD.

The phase 3 ENLIGHTED trial has reached the 50% patient enrollment threshold.

Van As makes the case for clinical evidence supporting the priority of SBRT, describing its convenience and cost-effectiveness without compromising outcomes.

Blanchard provides an update on the SABRE trial, assessing an iodinated hydrogel space used for SBRT treatment in patients with prostate cancer.

Dandapani highlights her team's promising findings around combination Ra-223, SBRT and ADT therapy for metastatic castrate sensitive prostate cancer.

Findings from GETUG 14 show short-term ADT with high-dose radiotherapy provided 5-year improved efficacy without increased risk of toxicity.